
Conversations in Drug Development
EU Pharma Reform 2026: What Every Developer Needs to Know
38 min•7 oktober 2026
Om avsnittet
In this episode, Katherine Bowen and Shalini Gupta discuss the EU pharmaceutical legislation reform — a comprehensive update to regulations and directives that will affect drug approval, orphan and paediatric rules, exclusivity incentives, EMA structure and timelines, supply obligations, environmental risk assessments, and transparency requirements.
Hosts outline the timeline, key practical impacts for sponsors, and recommended next steps: begin preparing now, align regulatory, market‑access and supply strategies, and monitor EMA guidance during the transition period.
Conversations in Drug Development med Boyds finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.